Delpharm Huningue

Delpharm, a leading Contract Development and Manufacturing Organization (CDMO) in the pharmaceutical industry, recently acquired a pharmaceutical production site in Meppel, the Netherlands, from Astellas. This acquisition strengthens Delpharm's capabilities in producing solid dosage forms and enhances its position for supplying the US market with FDA certification. Delpharm is recognized as one of the top 5 CDMOs globally, offering a wide range of pharmaceutical forms including sterile and non-sterile liquids, solid dosage forms, semi-solids, and biotech products. Delpharm emphasizes its expertise in development and regulatory affairs to support the introduction of new pharmaceutical products. The company, with a turnover of 1 billion euros and employing 6,500 individuals, focuses on innovation and quality to meet the needs of its diverse clientele. In line with its commitment to sustainability, Delpharm prioritizes developing its employees, responsible purchasing practices, Health, Safety, and Environment (HSE) standards, and maintaining a high level of product quality. Furthermore, Delpharm has expanded its pharmaceutical development services by acquiring a center for developing injectable drugs in the Netherlands. The company also offers expertise in analyzing drug substances and impurities through advanced technologies available at its development center in Delpharm Leiden. Additionally, Delpharm supports clients with projects involving microspheres, clinical trials, and the production of pre-filled syringes. By continuously adapting to the evolving needs of its clients, Delpharm demonstrates its commitment to being a strategic partner in the pharmaceutical industry. In conclusion, Delpharm's dedication to providing high-quality pharmaceutical manufacturing and development services, along with its strategic acquisitions and focus on innovation and sustainability, solidify its position as a key player in the global pharmaceutical CDMO sector.